Investing
Newmont (TSX:NGT,NYSE:NEM,ASX:NEM) is preparing to withdraw from the TSX, the latest in a string of moves to streamline operations and rein in costs following...
Hi, what are you looking for?
Technical analysts Kevin Wadsworth and Patrick Karim of NorthstarBadcharts.com share an update on the capital rotation process that they see unfolding, and explain what...
Statistics Canada released its December data for gross domestic product (GDP) by industry on Friday (February 27). While overall GDP increased 0.2 percent, the...
We also break down next week’s catalysts to watch to help you prepare for the week ahead. In this article: This week’s tech sector...
Panther Metals Plc (LSE: PALM), the exploration company focused on mineral projects in Canada, is pleased to provide an update for the Obonga Project’s...
Newmont (TSX:NGT,NYSE:NEM,ASX:NEM) is preparing to withdraw from the TSX, the latest in a string of moves to streamline operations and rein in costs following...
Barrick Mining (TSX:ABX,NYSE:B) has agreed to sell its Hemlo gold mine in Ontario, Canada, for up to US$1.09 billion, continuing the company’s shift away...
Perth, Australia (ABN Newswire) – Locksley Resources Ltd (ASX:LKY,OTC:LKYRF) (FRA:X5L) (OTCMKTS:LKYRF) is pleased to advise that the Company is advancing a significant expansion to...
Locksley Resources (LKY:AU) has announced Significant Enlargement of Exploration Program Download the PDF here. This post appeared first on investingnews.com
Carbonxt Group (CG1:AU) has announced Completion of Non-Renounceable Pro-Rata Entitlement Offer Download the PDF here. This post appeared first on investingnews.com
On Thursday (September 11), Canadian Prime Minister Mark Carney revealed the first tranche of projects selected by the newly created Major Projects Office. The...
Gold’s record-setting price run continued this week, with yet another new all-time high in the books. Silver also fared well, breaking US$42 per ounce....
Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to...
Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to...
Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to...